Roche receives CE mark for first IVD immunoassay blood test to identify carriers of ApoE4, a genetic variant present in up to 60% of patients diagnosed with Alzheimer's disease

Core Insights - Roche has received CE Mark approval for the Elecsys® Apolipoprotein E4 biomarker test, the first in-vitro diagnostic immunoassay to identify the ApoE4 gene variant in blood, which is present in 40-60% of Alzheimer's patients [1][2][5] - The test simplifies the diagnostic process for Alzheimer's disease by allowing quick identification of ApoE4 carriers, thus streamlining patient management and treatment decisions [2][4] - The Elecsys ApoE4 test is part of Roche's broader commitment to improving Alzheimer's care through advanced diagnostic tools and innovative therapies [7][8] Product Details - The Elecsys ApoE4 test uses a minimally-invasive blood sample to determine ApoE4 carrier status, which is clinically significant for guiding disease-modifying therapies (DMTs) [1][4][5] - The test demonstrated 100% concordance with genetic testing, accurately identifying all carriers and non-carriers [6] - It is designed to work alongside other Roche blood-based Alzheimer's biomarkers, enhancing the overall diagnostic journey [2][7] Market Context - Alzheimer's disease accounts for up to 70% of dementia cases globally and is projected to affect nearly 150 million people by 2050 [1][3] - The approval of the Elecsys ApoE4 test aligns with the 2024 Alzheimer's Association criteria, recognizing ApoE4 as a clinically relevant genetic risk factor for Alzheimer's [3][4] - Roche's position as a leader in both pharmaceuticals and diagnostics allows for a comprehensive approach to patient care in Alzheimer's disease [8]